Bausch Health Cos Inc. $BHC Shares Purchased by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. has increased its stake in Bausch Health Cos Inc. by 0.5%, holding 11,746,480 shares valued at approximately $76 million.
• Bausch Health's director, John Paulson, significantly raised his position by purchasing over 34 million shares, increasing his ownership to nearly 70.76 million shares.
• Bausch Health reported earnings of $0.90 per share in its latest quarter, missing analyst expectations, but achieved revenues of $2.57 billion, exceeding estimates.

Vanguard Group Inc. lifted its position in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 0.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,746,480 shares of the company's stock after acquiring an additional 61,621 shares during the quarter. Vanguard Group Inc. owned 3.24% of Bausch Health Cos worth $76,152,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BHC. Toronto Dominion Bank lifted its stake in Bausch Health Cos by 1.0% in the 4th quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock valued at $1,350,000 after buying an additional 1,712 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Bausch Health Cos by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after buying an additional 1,896 shares in the last quarter. SBI Securities Co. Ltd. lifted its stake in Bausch Health Cos by 244.2% in the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after buying an additional 3,001 shares in the last quarter. Cary Street Partners Financial LLC purchased a new stake in Bausch Health Cos in the 1st quarter valued at approximately $27,000. Finally, Viewpoint Capital Management LLC lifted its stake in Bausch Health Cos by 27.0% in the 1st quarter. Viewpoint Capital Management LLC now owns 24,000 shares of the company's stock valued at $155,000 after buying an additional 5,100 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Insider Transactions at Bausch Health Cos

In related news, Director John Paulson purchased 34,721,118 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the acquisition, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders acquired 44,316,834 shares of company stock valued at $369,628,560. 8.05% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BHC shares. Royal Bank Of Canada upped their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Trading Up 3.6%

Shares of BHC stock traded up $0.26 on Friday, reaching $7.41. 2,189,126 shares of the stock were exchanged, compared to its average volume of 4,518,157. The stock has a market cap of $2.74 billion, a P/E ratio of 28.50 and a beta of 0.41. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The firm has a 50 day moving average of $6.73 and a two-hundred day moving average of $6.06. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $9.85.

Bausch Health Cos (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). The firm had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.